RxDoctor Payments Data

van la, DO

Internal Medicine · Alhambra, CANPI 1417335134

Payments from drug & device makers

$1,848in general payments, 2019–2025

Across 41 payments — averaging $45.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$438
  • Novartis$183
  • Cvrx, Inc.$167
  • E.r. Squibb & Sons, L.L.C.$153
  • Boehringer Ingelheim$151
  • Shockwave Medical, Inc$150
  • plus $606 from 9 others

What the payments were for

  • Food & beverage$1,67591%
  • Education$1729%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,848 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$142,220
Medicare patients
428
Services billed
1,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin261$193,718
EliquisApixaban160$134,567
XareltoRivaroxaban60$44,778
EntrestoSacubitril/Valsartan25$22,627
MultaqDronedarone Hcl11$19,149
FarxigaDapagliflozin Propanediol15$11,336
BrilintaTicagrelor16$9,471
Ranolazine ErRanolazine78$9,157
Repatha SureclickEvolocumab11$8,395
Metoprolol Succinate358$3,502
Atorvastatin Calcium307$1,858
Losartan Potassium183$1,702
Nitroglycerin67$1,260
Ezetimibe80$1,181
Amlodipine Besylate199$1,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$151$193,718261 claims
NovartisEntresto$183$22,62725 claims
AstraZenecaFarxiga, Brilinta$125$20,80631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Alhambra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →